Citations (94)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (11)
Karthik Ravi, Andrea Franson, Morgan J. Homan, Holly Roberts, Manjunath P. Pai, Zachary Miklja, Miao He, Bo Wen, Lydia L. Benitez, Anthony J. Perissinotti, Dale L. Bixby, Carl Koschmann & Bernard L. Marini. (2021) Comparative pharmacokinetic analysis of the blood-brain barrier penetration of dasatinib and ponatinib in mice. Leukemia & Lymphoma 62:8, pages 1990-1994.
Read now
Read now
Xavier Thomas & Caroline Le Jeune. (2016) Treating adults with acute lymphocytic leukemia: new pharmacotherapy options. Expert Opinion on Pharmacotherapy 17:17, pages 2319-2330.
Read now
Read now
Xavier Thomas & Maël Heiblig. (2016) The development of agents targeting the BCR-ABL tyrosine kinase as Philadelphia chromosome-positive acute lymphoblastic leukemia treatment. Expert Opinion on Drug Discovery 11:11, pages 1061-1070.
Read now
Read now
Elias J. Jabbour, Timothy P. Hughes, Jorge E. Cortés, Hagop M. Kantarjian & Andreas Hochhaus. (2014) Potential mechanisms of disease progression and management of advanced-phase chronic myeloid leukemia. Leukemia & Lymphoma 55:7, pages 1451-1462.
Read now
Read now
Hong-Sheng Zhou, Min Dai, Yongqiang Wei, Qiang Wang, Na Xu, Changxin Yin & Fanyi Meng. (2013) Isolated central nervous system relapse in patient with blast-crisis chronic myeloid leukemia in durable complete cytogenetic remission on dasatinib treatment: pharmacokinetics and ABL mutation analysis in cerebrospinal fluid. Leukemia & Lymphoma 54:7, pages 1557-1559.
Read now
Read now
Atsushi Satake, Masaya Okada, Takako Asada, Kyoko Fujita, Kazuhiro Ikegame, Hiroya Tamaki, Yoshihiro Fujimori & Hiroyasu Ogawa. (2010) Dasatinib is effective against optic nerve infiltration of Philadelphia chromosome-positive acute lymphoblastic leukemia. Leukemia & Lymphoma 51:10, pages 1920-1922.
Read now
Read now
Charles Chuah & Junia V Melo. (2009) Targeted treatment of imatinib-resistant chronic myeloid leukemia: Focus on dasatinib. OncoTargets and Therapy 2, pages 83-94.
Read now
Read now
Mike G. Martin, John F. Dipersio & Geoffrey L. Uy. (2009) Management of the advanced phases of chronic myelogenous leukemia in the era of tyrosine kinase inhibitors. Leukemia & Lymphoma 50:1, pages 14-23.
Read now
Read now
Peter Valent. (2007) Imatinib-resistant chronic myeloid leukemia (CML): Current concepts on pathogenesis and new emerging pharmacologic approaches. Biologics: Targets and Therapy 1:4, pages 433-448.
Read now
Read now
Seong-Wook Yun, Alexa Ertmer, Eckhard Flechsig, Sabine Gilch, Peter Riederer, Manfred Gerlach, Hermann M Schätzl & Michael A Klein. (2007) The tyrosine kinase inhibitor imatinib mesylate delays prion neuroinvasion by inhibiting prion propagation in the periphery. Journal of Neurovirology 13:4, pages 328-337.
Read now
Read now
Cindy Q Xia, Johnny J Yang & Liang-Shang Gan. (2005) Breast cancer resistance protein in pharmacokinetics and drug–drug interactions. Expert Opinion on Drug Metabolism & Toxicology 1:4, pages 595-611.
Read now
Read now
Articles from other publishers (83)
Zaid Abdel Rahman & Partow Kebriaei. (2023) SOHO State of the Art Updates and Next Questions | Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia in Adults: Therapeutic Options and Challenges in 2023. Clinical Lymphoma Myeloma and Leukemia 23:11, pages 779-785.
Crossref
Crossref
Sarah Allegra, Emma Dondi, Francesco Chiara & Silvia De Francia. (2023) Pharmacokinetics of Four Tyrosine Kinase Inhibitors in Adult and Paediatric Chronic Myeloid Leukaemia Patients. Biomedicines 11:9, pages 2478.
Crossref
Crossref
Zoltán Köllő, Miklós Garami, István Vincze, Barna Vásárhelyi & Gellért Karvaly. (2023) Therapeutic Monitoring of Orally Administered, Small-Molecule Anticancer Medications with Tumor-Specific Cellular Protein Targets in Peripheral Fluid Spaces—A Review. Pharmaceutics 15:1, pages 239.
Crossref
Crossref
Yuanxin Zhu, Ying Zhu, Lei Miao, Tao Jia, Jianping Mao, Lianguo Xue & Ying Wang. (2023) Comparison of the Efficacy and Safety of Ponatinib and Dasatinib in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia With Central Nervous System Relapse: A Retrospective Study. Technology in Cancer Research & Treatment 22.
Crossref
Crossref
Sachit A. Patel & Jill C. Beck. (2022) Pediatric Chronic Myelogenous Leukemia in T-lineage Blast Crisis: A Reminder in Relevance. Journal of Pediatric Hematology/Oncology 44:3, pages e707-e708.
Crossref
Crossref
Patrick A. BrownBijal ShahAnjali AdvaniPatricia AounMichael W. BoyerPatrick W. BurkeDaniel J. DeAngeloShira DinnerAmir T. FathiJordan GauthierNitin JainSuzanne KirbyMichaela LiedtkeMark LitzowAaron LoganSelina LugerLori J. ManessStephanie MassaroRyan J. MattisonWilliam MayOlalekan OluwoleJae ParkAmanda PrzespolewskiSravanti RangarajuJeffrey E. RubnitzGeoffrey L. UyMadhuri VusirikalaMatthew Wieduwilt, Beth LynnRyan A. BerardiDeborah A. Freedman-CassMallory Campbell. (2021) Acute Lymphoblastic Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network 19:9, pages 1079-1109.
Crossref
Crossref
Raju Saka, Naveen Chella & Wahid Khan. (2021) Development of Imatinib Mesylate-Loaded Liposomes for Nose to Brain Delivery: In Vitro and In Vivo Evaluation. AAPS PharmSciTech 22:5.
Crossref
Crossref
Xiaoyuan Gong, Le Li, Hui Wei, Bingcheng Liu, Chunlin Zhou, Guangji Zhang, Kaiqi Liu, Dong Lin, Benfa Gong, Shuning Wei, Yan Li, Yingchang Mi, Ying Wang & Jianxiang Wang. (2021) A Higher Dose of Dasatinib May Increase the Possibility of Crossing the Blood–brain Barrier in the Treatment of Patients With Philadelphia Chromosome–positive Acute Lymphoblastic Leukemia. Clinical Therapeutics 43:7, pages 1265-1271.e1.
Crossref
Crossref
Jia‐Bao He, Xin Zhang, Zi‐Wen Guo, Miao‐Miao Liu, Na Xu, Fen Huang, Zhi‐Ping Fan, Li Xuan, Lan Deng, Shu‐Hua Lin, Jun Xu, Jing Sun & Qi‐Fa Liu. (2019) Ponatinib therapy in recurrent Philadelphia chromosome‐positive central nervous system leukemia with T315I mutation after Allo‐HSCT. International Journal of Cancer 147:4, pages 1071-1077.
Crossref
Crossref
Iman Abou Dalle, Hagop M. Kantarjian, Nicholas J. Short, Marina Konopleva, Nitin Jain, Guillermo Garcia‐Manero, Rebecca Garris, Wei Qiao, Jorge E. Cortes, Susan O'Brien, Partow Kebriaei, Tapan Kadia, Elias Jabbour & Farhad Ravandi. (2019) Philadelphia chromosome‐positive acute lymphoblastic leukemia at first relapse in the era of tyrosine kinase inhibitors. American Journal of Hematology 94:12, pages 1388-1395.
Crossref
Crossref
Kurt A. Jaeckle, S. K. Anderson, Erin L. Twohy, Jesse G. Dixon, Caterina Giannini, Robert Jenkins, Merrill J. Egorin, Jann N. Sarkaria, Paul D. Brown, P. J. Flynn, John Schwerkoske, Jan C. Buckner & Evanthia Galanis. (2019) Phase I-II trial of imatinib mesylate (Gleevec; STI571) in treatment of recurrent oligodendroglioma and mixed oligoastrocytoma. North central cancer treatment group study N0272 (ALLIANCE/NCCTG). Journal of Neuro-Oncology 143:3, pages 573-581.
Crossref
Crossref
Muhammad Raza Shah, Muhammad Imran & Shafi Ullah. 2019. Nanocarriers for Cancer Diagnosis and Targeted Chemotherapy. Nanocarriers for Cancer Diagnosis and Targeted Chemotherapy
1
21
.
Akira Chiba, Takashi Toya, Hideaki Mizuno, Junji Tokushige, Fumihiko Nakamura, Kumi Nakazaki & Mineo Kurokawa. (2018) Chronic myelogenous leukemia presenting with central nervous system infiltration, successfully treated with central nervous system-directed chemotherapy followed by allogeneic stem cell transplantation. International Journal of Hematology 108:6, pages 640-646.
Crossref
Crossref
Cristina Trejo-Solís, Norma Serrano-Garcia, Ángel Escamilla-Ramírez, Rosa Castillo-Rodríguez, Dolores Jimenez-Farfan, Guadalupe Palencia, Minerva Calvillo, Mayra Alvarez-Lemus, Athenea Flores-Nájera, Arturo Cruz-Salgado & Julio Sotelo. (2018) Autophagic and Apoptotic Pathways as Targets for Chemotherapy in Glioblastoma. International Journal of Molecular Sciences 19:12, pages 3773.
Crossref
Crossref
William J. Netzer, Karima Bettayeb, Subhash C. Sinha, Marc Flajolet, Paul Greengard & Victor Bustos. (2017) Gleevec shifts APP processing from a β-cleavage to a nonamyloidogenic cleavage. Proceedings of the National Academy of Sciences 114:6, pages 1389-1394.
Crossref
Crossref
Timothy P. Heffron. (2016) Small Molecule Kinase Inhibitors for the Treatment of Brain Cancer. Journal of Medicinal Chemistry 59:22, pages 10030-10066.
Crossref
Crossref
Sebastian Giebel, Anna Czyz, Oliver Ottmann, Frederic Baron, Eolia Brissot, Fabio Ciceri, Jan J. Cornelissen, Jordi Esteve, Norbert-Claude Gorin, Bipin Savani, Christoph Schmid, Mohamad Mohty & Arnon Nagler. (2016) Use of tyrosine kinase inhibitors to prevent relapse after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A position statement of the Acute Leukemia Working Party of the. Cancer 122:19, pages 2941-2951.
Crossref
Crossref
Xavier Thomas & Maël Heiblig. (2016) Diagnostic and treatment of adult Philadelphia chromosome-positive acute lymphoblastic leukemia. International Journal of Hematologic Oncology 5:2, pages 77-90.
Crossref
Crossref
Xavier Thomas & Caroline Le Jeune. (2016) Current Management of Adult Acute Lymphoblastic Leukaemia: Emerging Insights and Outstanding Questions. EMJ Hematology, pages 117-128.
Crossref
Crossref
Eric J Wigton, Scott B Thompson, Robert A Long & Jordan Jacobelli. (2016) Myosin-IIA regulates leukemia engraftment and brain infiltration in a mouse model of acute lymphoblastic leukemia. Journal of Leukocyte Biology 100:1, pages 143-153.
Crossref
Crossref
N. Heidari, N. Saki, L. De Filippis, M. Shahjahani, A. Teimouri & A. Ahmadzadeh. (2015) Central nervous system niche involvement in the leukemia. Clinical and Translational Oncology 18:3, pages 240-250.
Crossref
Crossref
SHIUE-WEI LAI, TZU-CHUAN HUANG, JIA-HONG CHEN, YI-YING WU & PING-YING CHANG. (2015) Dasatinib as the salvage therapy for chronic myeloid leukemia with blast crisis and central nervous system involvement: A case report. Oncology Letters 9:4, pages 1957-1961.
Crossref
Crossref
Rohit Gulati, Yaser Alkhatib, Vijayalakshmi Donthireddy, Michelle Madden Felicella, Madhu P. Menon & Kedar V. Inamdar. (2015) Isolated Ocular Manifestation of Relapsed Chronic Myelogenous Leukemia Presenting as Myeloid Blast Crisis in a Patient on Imatinib Therapy: A Case Report and Review of the Literature. Case Reports in Pathology 2015, pages 1-7.
Crossref
Crossref
Juliana Gomez & Victor Duenas. (2015) Isolated Central Nervous System Relapse in Chronic Myeloid Leukemia. Case Reports in Medicine 2015, pages 1-4.
Crossref
Crossref
Mitsutoshi Nakada, Daisuke Kita, Takuya Watanabe, Yutaka Hayashi & Jun-ichiro Hamada. (2014) The mechanism of chemoresistance against tyrosine kinase inhibitors in malignant glioma. Brain Tumor Pathology 31:3, pages 198-207.
Crossref
Crossref
Mi-Jung Park, Pil-Whan Park, Yiel-Hea Seo, Kyung-Hee Kim, Ja-Young Seo, Ji-Hun Jeong, Moon Jin Kim, Jin-Woo Jeong, Jeong-Yeal Ahn & Jinny Park. (2014) A Case of Isolated Lymphoblastic Relapse of the Central Nervous System in a Patient with Chronic Myelogenous Leukemia Treated with Imatinib. Annals of Laboratory Medicine 34:3, pages 247-251.
Crossref
Crossref
Ohad Benjamini, Theresa Liu Dumlao, Hagop Kantarjian, Susan O'Brien, Guillermo Garcia-Manero, Stefan Faderl, Jeffrey Jorgensen, Rajyalakshmi Luthra, Rebecca Garris, Deborah Thomas, Partow Kebriaei, Richard Champlin, Elias Jabbour, Jan Burger, Jorge Cortes & Farhad Ravandi. (2014) Phase II trial of HyperCVAD and Dasatinib in patients with relapsed Philadelphia chromosome positive acute lymphoblastic leukemia or blast phase chronic myeloid leukemia. American Journal of Hematology 89:3, pages 282-287.
Crossref
Crossref
Michael Tagen & Clinton F. Stewart. 2014. Handbook of Anticancer Pharmacokinetics and Pharmacodynamics. Handbook of Anticancer Pharmacokinetics and Pharmacodynamics
625
659
.
S. Durmus, N. Xu, R.W. Sparidans, E. Wagenaar, J.H. Beijnen & A.H. Schinkel. (2013) P-glycoprotein (MDR1/ABCB1) and breast cancer resistance protein (BCRP/ABCG2) restrict brain accumulation of the JAK1/2 inhibitor, CYT387. Pharmacological Research 76, pages 9-16.
Crossref
Crossref
Jana Portnow, Behnam Badie, Susan Markel, An Liu, Massimo D?Apuzzo, Paul Frankel, Rahul Jandial & Timothy W. Synold. (2013) A neuropharmacokinetic assessment of bafetinib, a second generation dual BCR-Abl/Lyn tyrosine kinase inhibitor, in patients with recurrent high-grade gliomas. European Journal of Cancer 49:7, pages 1634-1640.
Crossref
Crossref
Mitsutaka Nishimoto, Hirohisa Nakamae, Ki-Ryang Koh, Saori Kosaka, Kana Matsumoto, Kunihiko Morita, Hideo Koh, Takahiko Nakane, Masahiko Ohsawa & Masayuki Hino. (2013) Dasatinib Maintenance Therapy after Allogeneic Hematopoietic Stem Cell Transplantation for an Isolated Central Nervous System Blast Crisis in Chronic Myelogenous Leukemia. Acta Haematologica 130:2, pages 111-114.
Crossref
Crossref
Annette Nørregaard, Stine Skov Jensen, Jesper Kolenda, Charlotte Aaberg-Jessen, Karina Garnier Christensen, Poul Henning Jensen, Henrik Daa Schrøder & Bjarne Winther Kristensen. (2011) Effects of Chemotherapeutics on Organotypic Corticostriatal Slice Cultures Identified by A Panel of Fluorescent and Immunohistochemical Markers. Neurotoxicity Research 22:1, pages 43-58.
Crossref
Crossref
Hanny Haaxma-Reiche. 2012. Neuro-Oncology Part II. Neuro-Oncology Part II
711
729
.
Sagar Agarwal, Ramola Sane, Rajneet Oberoi, John R. Ohlfest & William F. Elmquist. (2011) Delivery of molecularly targeted therapy to malignant glioma, a disease of the whole brain. Expert Reviews in Molecular Medicine 13.
Crossref
Crossref
Shih-Feng Cho, Ta-Chih Liu, Chi-Yu Lu & Chao-Sung Chang. (2010) Epidural leukemic involvement and intracranial hemorrhage as initial manifestations in a newly diagnosed chronic myeloid leukemia patient. Annals of Hematology 90:5, pages 607-609.
Crossref
Crossref
Farhad Ravandi. (2011) Managing Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Role of Tyrosine Kinase Inhibitors. Clinical Lymphoma Myeloma and Leukemia 11:2, pages 198-203.
Crossref
Crossref
Nidal BoulosHeather L. MulderChristopher R. CalabreseJeffrey B. MorrisonJerold E. RehgMary V. Relling, Charles J. Sherr & Richard T. Williams. (2011) Chemotherapeutic agents circumvent emergence of dasatinib-resistant BCR-ABL kinase mutations in a precise mouse model of Philadelphia chromosome–positive acute lymphoblastic leukemia. Blood 117:13, pages 3585-3595.
Crossref
Crossref
Vivek A. Bhadri, Keshan Satharasinghe, Ella Sugo, Draga Barbaric & Toby N. Trahair. (2011) Excellent response to dasatinib of childhood Philadelphia positive intracranial acute lymphoblastic leukaemia tumours. British Journal of Haematology 152:3, pages 347-349.
Crossref
Crossref
Daniel J. DeAngelo. 2011. Adult Acute Lymphocytic Leukemia. Adult Acute Lymphocytic Leukemia
277
296
.
Deborah A. Thomas, Susan O’Brien, Stefan Faderl & Hagop Kantarjian. 2011. Adult Acute Lymphocytic Leukemia. Adult Acute Lymphocytic Leukemia
233
255
.
Olga Sala‐Torra & Jerald P. Radich. 2010. Leukemias: Principles and Practice of Therapy. Leukemias: Principles and Practice of Therapy
228
243
.
D. Focosi & R. E. Kast. (2010) Improving imatinib delivery to central nervous system. Internal Medicine Journal 40:4, pages 318-319.
Crossref
Crossref
Anish Thomas, Constance K. Stein, Teresa C. Gentile & Chirag M. Shah. (2010) Isolated CNS relapse of CML after bone marrow transplantation. Leukemia Research 34:4, pages e113-e114.
Crossref
Crossref
Matthias Holdhoff, Jeffrey G. Supko, Gary L. Gallia, Christine L. Hann, David Bonekamp, Xiaobu Ye, Bing Cao, Alessandro Olivi & Stuart A. Grossman. (2009) Intratumoral concentrations of imatinib after oral administration in patients with glioblastoma multiforme. Journal of Neuro-Oncology 97:2, pages 241-245.
Crossref
Crossref
Philippe Aftimos & Fady Nasr. (2009) Isolated CNS lymphoid blast crisis in a patient with imatinib-resistant chronic myelogenous leukemia: Case report and review of the literature. Leukemia Research 33:11, pages e178-e180.
Crossref
Crossref
Shuiying Hu, Zhaoyuan Chen, Ryan Franke, Shelley Orwick, Ming Zhao, Michelle A. Rudek, Alex Sparreboom & Sharyn D. Baker. (2009) Interaction of the Multikinase Inhibitors Sorafenib and Sunitinib with Solute Carriers and ATP-Binding Cassette Transporters. Clinical Cancer Research 15:19, pages 6062-6069.
Crossref
Crossref
Farhad Ravandi & Partow Kebriaei. (2009) Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Hematology/Oncology Clinics of North America 23:5, pages 1043-1063.
Crossref
Crossref
Jeroen J.W.M. Janssen, Henk W. Berendse, Gerrit‐Jan Schuurhuis, Pauline A. Merle & Gert J. Ossenkoppele. (2009) A 51‐year‐old male CML patient with progressive hearing loss, confusion, ataxia, and aphasia during imatinib treatment. American Journal of Hematology 84:10, pages 679-682.
Crossref
Crossref
Ying Chen, Sagar Agarwal, Naveed M. Shaik, Cliff Chen, Zheng Yang & William F. Elmquist. (2009) P-glycoprotein and Breast Cancer Resistance Protein Influence Brain Distribution of Dasatinib. Journal of Pharmacology and Experimental Therapeutics 330:3, pages 956-963.
Crossref
Crossref
James W. Vardiman. (2009)
Chronic Myelogenous Leukemia,
BCR
-
ABL1
+
. American Journal of Clinical Pathology 132:2, pages 250-260.
Crossref
Crossref
Jurjen S. Lagas, Robert A.B. van Waterschoot, Vicky A.C.J. van Tilburg, Michel J. Hillebrand, Nienke Lankheet, Hilde Rosing, Jos H. Beijnen & Alfred H. Schinkel. (2009) Brain Accumulation of Dasatinib Is Restricted by P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) and Can Be Enhanced by Elacridar Treatment. Clinical Cancer Research 15:7, pages 2344-2351.
Crossref
Crossref
Oliver G. Ottmann & Heike Pfeifer. (2009) Management of Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL). Hematology 2009:1, pages 371-381.
Crossref
Crossref
Arturo Vega-Ruiz, Susan O?Brien, Jorge Cortes, Partow Kebriaei, Deborah Thomas, Hagop Kantarjian & Farhad Ravandi. (2008) Secondary myelodysplastic syndrome in a patient with Philadelphia-positive acute lymphoblastic leukemia after achieving a major molecular response with hyperCVAD plus imatinib mesylate. Leukemia Research 32:9, pages 1468-1471.
Crossref
Crossref
Kimmo Porkka, Perttu Koskenvesa, Tuija LundánJohanna RimpiläinenSatu Mustjoki, Richard SmyklaRobert WildRoger LuoMontserrat ArnanBenoit BrethonLydia EccersleyHenrik Hjorth-HansenMartin HöglundHana KlamovaHåvar KnutsenSuhag ParikhEmmanuel RaffouxFranz GruberFinella Brito-BabapulleHervé DombretRafael F. DuarteErkki Elonen, Ron PaquetteC. Michel Zwaan & Francis Y. F. Lee. (2008) Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome–positive leukemia. Blood 112:4, pages 1005-1012.
Crossref
Crossref
Peter Valent. (2008) Emerging stem cell concepts for imatinib-resistant chronic myeloid leukaemia: implications for the biology, management, and therapy of the disease. British Journal of Haematology 142:3, pages 361-378.
Crossref
Crossref
Daniel J. DeAngelo & Richard M. Stone. (2008) New agents for the treatment of patients with acute lymphoblastic leukemia. Current Hematologic Malignancy Reports 3:3, pages 135-143.
Crossref
Crossref
Vasantha Thavaraj & Rachna Seth. (2008) Prophylaxis of central nervous system leukemia: a case of chronic myeloid leukemia with lymphoid blast crisis treated with imatinib mesylate. World Journal of Pediatrics 4:2, pages 145-147.
Crossref
Crossref
Olga Sala-Torra & Jerald P. Radich. 2008. Acute Leukemias. Acute Leukemias
177
189
.
D. B. Hoelzinger, T. Demuth & M. E. Berens. (2007) Autocrine Factors That Sustain Glioma Invasion and Paracrine Biology in the Brain Microenvironment. JNCI Journal of the National Cancer Institute 99:21, pages 1583-1593.
Crossref
Crossref
K. J. Aichberger, S. Herndlhofer, H. Agis, W. R. Sperr, H. Esterbauer, W. Rabitsch, P. Knöbl, O. A. Haas, R. Thalhammer, I. Schwarzinger, C. Sillaber, U. Jäger & P. Valent. (2007) Liposomal cytarabine for treatment of myeloid central nervous system relapse in chronic myeloid leukaemia occurring during imatinib therapy. European Journal of Clinical Investigation 37:10, pages 808-813.
Crossref
Crossref
Deborah A. Thomas, Susan O’Brien, Jorge Cortes & Hagop Kantarjian. (2007) New approaches to the management of Philadelphia chromosome-positive acute lymphocytic leukemia. Current Hematologic Malignancy Reports 2:3, pages 183-189.
Crossref
Crossref
C Brendel, C Scharenberg, M Dohse, R W Robey, S E Bates, S Shukla, S V Ambudkar, Y Wang, G Wennemuth, A Burchert, U Boudriot & A Neubauer. (2007) Imatinib mesylate and nilotinib (AMN107) exhibit high-affinity interaction with ABCG2 on primitive hematopoietic stem cells. Leukemia 21:6, pages 1267-1275.
Crossref
Crossref
Sarah A Cross & Katherine A Lyseng-Williamson. (2007) Imatinib. Drugs 67:17, pages 2645-2654.
Crossref
Crossref
Asumi YokotaShinya KimuraSatohiro MasudaEishi AshiharaJunya KurodaKiyoshi SatoYuri KamitsujiEri KawataYasuyuki DeguchiYoshimasa UrasakiYasuhito TeruiMartin Ruthardt, Takanori UedaKiyohiko HatakeKen-ichi InuiTaira Maekawa. (2006) INNO-406, a novel BCR-ABL/Lyn dual tyrosine kinase inhibitor, suppresses the growth of Ph+ leukemia cells in the central nervous system, and cyclosporine A augments its in vivo activity. Blood 109:1, pages 306-314.
Crossref
Crossref
Deborah A. Thomas. (2007) Philadelphia Chromosome–Positive Acute Lymphocytic Leukemia: A New Era of Challenges. Hematology 2007:1, pages 435-443.
Crossref
Crossref
N.S. NingarajB.P. SalimathU.T. SankpalR PereraT Vats. (2017) Targeted Brain Tumor Treatment-Current Perspectives. Drug Target Insights 2, pages 117739280700200.
Crossref
Crossref
Nancy D. Doolittle. 2007. Brain Metastases. Brain Metastases
169
183
.
James M.G. Larkin & Tim Eisen. (2006) Kinase inhibitors in the treatment of renal cell carcinoma. Critical Reviews in Oncology/Hematology 60:3, pages 216-226.
Crossref
Crossref
. 2006. Wiley Handbook of Current and Emerging Drug Therapies. Wiley Handbook of Current and Emerging Drug Therapies.
. 2006. Wiley Handbook of Current and Emerging Drug Therapies. Wiley Handbook of Current and Emerging Drug Therapies.
B?rbara Mel?ndez, Concepci?n Fia?o, Yolanda Ruano, Jose L. Hern?ndez-Moneo, Manuela Mollejo & Pedro Martinez. (2006) BCR gene disruption in a pilomyxoid astrocytoma. Neuropathology 26:5, pages 442-446.
Crossref
Crossref
Tibor Kovacsovics & Richard T. Maziarz. (2006) Philadelphia chromosome-positive acute lymphoblastic leukemia: Impact of imatinib treatment on remission induction and allogeneic stem cell transplantation. Current Oncology Reports 8:5, pages 343-351.
Crossref
Crossref
Jeffrey A. Zonder & Charles A. Schiffer. (2006) Update on practical aspects of the treatment of chronic myeloid leukemia with imatinib mesylate. Current Hematologic Malignancy Reports 1:3, pages 141-151.
Crossref
Crossref
Giuliana Alimena, Massimo Breccia, Roberto Latagliata, Ida Carmosino, Eleonora Russo, Francesca Biondo, Daniela Diverio, Marco Mancini, Mauro Nanni & Franco Mandelli. (2006) Sudden blast crisis in patients with Philadelphia chromosome‐positive chronic myeloid leukemia who achieved complete cytogenetic remission after imatinib therapy. Cancer 107:5, pages 1008-1013.
Crossref
Crossref
Irene A.G. Roberts & Inderjeet S. Dokal. 2006. Pediatric Hematology. Pediatric Hematology
384
404
.
Hyun Jung Kim, Chul Won Jung, Kihyun Kim, Jin Seok Ahn, Won Seog Kim, Kwan Park, Young Hye Ko, Won Ki Kang & Keunchil Park. (2006) Isolated Blast Crisis in CNS in a Patient With Chronic Myelogenous Leukemia Maintaining Major Cytogenetic Response After Imatinib. Journal of Clinical Oncology 24:24, pages 4028-4029.
Crossref
Crossref
Patrick Y. Wen, W.K. Alfred Yung, Kathleen R. Lamborn, Patricia L. Dahia, Yanfeng Wang, Bin Peng, Lauren E. Abrey, Jeffrey Raizer, Timothy F. Cloughesy, Karen Fink, Mark Gilbert, Susan Chang, Larry Junck, David Schiff, Frank Lieberman, Howard A. Fine, Minesh Mehta, H. Ian Robins, Lisa M. DeAngelis, Morris D. Groves, Vinay K. Puduvalli, Victor Levin, Charles Conrad, Elizabeth A. Maher, Kenneth Aldape, Michael Hayes, Laurie Letvak, Merrill J. Egorin, Renaud Capdeville, Richard Kaplan, Anthony J. Murgo, Charles Stiles & Michael D. Prados. (2006) Phase I/II Study of Imatinib Mesylate for Recurrent Malignant Gliomas: North American Brain Tumor Consortium Study 99-08. Clinical Cancer Research 12:16, pages 4899-4907.
Crossref
Crossref
Thomas C. Harding, Alshad S. Lalani, Byron N. Roberts, Satya Yendluri, Bo Luan, Kathryn E. Koprivnikar, Melissa Gonzalez-Edick, Guang Huan-Tu, Randy Musterer, Melinda J. VanRoey, Tomoko Ozawa, Richard A. LeCouter, Dennis Deen, Peter J. Dickinson & Karin Jooss. (2006) AAV Serotype 8-Mediated Gene Delivery of a Soluble VEGF Receptor to the CNS for the Treatment of Glioblastoma. Molecular Therapy 13:5, pages 956-966.
Crossref
Crossref
Susannah Motl, Yanli Zhuang, Christopher M Waters & Clinton F Stewart. (2006) Pharmacokinetic Considerations in the Treatment of CNS Tumours. Clinical Pharmacokinetics 45:9, pages 871-903.
Crossref
Crossref
K-H Lee, J-H Lee, S-J Choi, J-H Lee, M Seol, Y-S Lee, W-K Kim, J-S Lee, E-J Seo, S Jang, C-J Park & H-S Chi. (2005) Clinical effect of imatinib added to intensive combination chemotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Leukemia 19:9, pages 1509-1516.
Crossref
Crossref
Mitsuhiro Matsuda, Yasuyoshi Morita, Takahiro Shimada, Junichi Miyatake, Chikara Hirase, Miyako Tanaka, Yoichi Tatsumi, Yasuhiro Maeda & Akihisa Kanamaru. (2005) Extramedullary Blast Crisis Derived from 2 Different Clones in the Central Nervous System and Neck during Complete Cytogenetic Remission of Chronic Myelogenous Leukemia Treated with Imatinib Mesylate. International Journal of Hematology 81:4, pages 307-309.
Crossref
Crossref
Robert L. IlariaJr.Jr.. (2005) Pathobiology of Lymphoid and Myeloid Blast Crisis and Management Issues. Hematology 2005:1, pages 188-194.
Crossref
Crossref
. (2004) Current awareness: Pharmacoepidemiology and drug safety. Pharmacoepidemiology and Drug Safety 13:5.
Crossref
Crossref